{"prompt": "['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', '13', 'ATTACHMENT 1: SUBSTANTIAL AMENDMENT 3', 'I. The purpose of this amendment is:', 'Substantial Changes', '1. Add a Crossover Extension (COE) to Study Design', 'DESCRIPTION OF CHANGE:', 'A COE is added to the study design. Details of this extension amendment are added as', 'Appendix 12.10 and include a rationale, enrollment criteria, schedule of assessments,', 'duration of treatment and discontinuation criteria.', 'RATIONALE:', 'A COE is added for when the enfortumab vedotin (EV)-301 interim analysis results in a', 'positive outcome.', 'Nonsubstantial Changes', '1. Update Clinical Research Contact', 'DESCRIPTION OF CHANGE:', 'Contact details for the clinical research contact are revised.', 'RATIONALE:', 'This change is made due to changes to study personnel.', '2.', 'Update Schedule of Assessments', 'DESCRIPTION OF CHANGE:', 'In Table 2, the row for Subsequent Dosing Cycles is revised to specify cycles 3, 4, 6, 8 and', '10 and footnotes A and C are updated with cycle numbers.', 'In Table 3, footnote A is updated to include cycles 8 and 10.', 'RATIONALE:', 'This change is made because the pharmacokinetics of EV (antibody drug conjugate, total', 'antibody and monomethyl auristatin E) reaches steady-state by end of cycle 1 and', 'immunogenicity of EV is low based on previous studies, sufficient pharmacokinetic and', 'antitherapeutic antibodies data are collected by cycle 10 and most patients are off the study', 'by cycle 10.', '3. Update Response Evaluable Set (RES)', 'DESCRIPTION OF CHANGE:', '14 Sep 2020', 'Astellas', 'Page 128 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'The definition of the RES is updated to remove the requirement that subjects had at least 6', 'months of follow-up since randomization.', 'RATIONALE:', 'This revision is made based on regulatory agency feedback.', '4. Add Clarification to Efficacy Analysis', 'DESCRIPTION OF CHANGE:', 'Additional text is added to clarify when progression-free survival on study therapy (PFS1),', 'overall response rate (ORR) and disease control rate (DCR) can be tested.', 'RATIONALE:', 'This revision is made due to enrollment completion earlier. The multiplicity strategy was', 'updated accordingly.', '5. Update Duration of Response', 'DESCRIPTION OF CHANGE:', 'Additional text is added to clarify when radiological progression will be censored.', 'RATIONALE:', 'This revision is made to update the censor rules for PFS1 and duration of response (DOR)', 'to also censor the progressive disease (PD) or death after 2 or more missed disease', 'assessments based on regulatory agency feedback.', '6. Clarify Progression Free Survival', 'DESCRIPTION OF CHANGE:', 'Additional text is added to clarify the requirements for progression free survival.', 'RATIONALE:', 'This revision is made to update the censor rules for PFS1 and DOR to also censor the PD', 'or death after 2 or more missed disease assessments based on regulatory agency feedback.', '7. Minor Administrative-type Changes', 'DESCRIPTION OF CHANGE:', 'Include minor administrative-type changes (e.g., typos, format, numbering and consistency', 'throughout the protocol), add COE to the list of abbreviations and update an exploratory', 'endpoint in the synopsis to match the same endpoint in the body of the protocol.', 'RATIONALE:', 'To provide clarifications to the protocol and to ensure complete understanding of study', 'procedures.', '14 Sep 2020', 'Astellas', 'Page 129 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'II. Amendment Summary of Changes:', 'IIA. Substantial Changes', '12 Appendices', 'ADDED:', '12.10 Crossover Extension', 'Note: The crossover extension study described below and outlined in the Crossover', 'Extension (COE) schematic [Figure 2) will be conducted if the EV-301 Interim', 'Analysis results in a positive outcome. With the exception of those procedures and', 'processes indicated below, this extension study will be performed using the same', 'general approach as described in the protocol. Refer to the main protocol for any', 'study details not contained in the supplemental COE appendix.', '12.10.1 Rationale', 'Upon decision to stop the study for efficacy based on statistically significant os result', 'favoring EV, all eligible Arm B subjects can be evaluated for eligibility for COE EV', 'treatment at the discretion of the subject and investigator. Day 1 of the COE will', 'occur after COE informed consent form is signed and eligibility is confirmed.', 'Treatment with EV will be stopped upon disease progression and/or when', 'discontinuation criteria are met [Section 12.10.5 Duration of Treatment and Criteria', 'for Discontinuation). Arm B Subjects who do not participate in the COE will', 'continue to follow Arm B protocol procedures.', '12.10.2 Inclusion Criteria', 'Subject is eligible for the COE if they continue to meet all inclusion criteria from the', 'main protocol in addition to the following when the patient is evaluated for eligibility', 'to participate in the COE portion of the study:', '1. IRB/IEC approved written COE informed consent and privacy language as per', 'national regulations (e.g., HIPAA Authorization for US sites) must be obtained', 'from the subject prior to any study-related procedures (including withdrawal of', 'prohibited medication, if applicable).', '2. Subject was randomized to Arm B and is either currently on study treatment or', 'has discontinued study treatment due to intolerance, AE or progression of disease,', 'has not started a new systemic anticancer treatment and is still participating in', 'the follow up phase of the study.', 'Waivers to the COE inclusion criteria will NOT be provided.', '12.10.3 Exclusion Criteria', 'Subject will be excluded from participation in the COE if they meet any of the', 'exclusion criteria listed in the main protocol or if any of the following apply when the', 'patient is evaluated for eligibility to participate in the COE portion of the study:', '1. Subject has been diagnosed with a new malignancy while on Arm B in the EV-301', 'study. Subjects with nonmelanoma skin cancer, localized prostate cancer treated', 'with curative intent with no evidence of progression, low-risk or very low-risk', '(per standard guidelines) localized prostate cancer under active', '14 Sep 2020', 'Astellas', 'Page 130 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']\n\n###\n\n", "completion": "END"}